Related Experiment Videos
[Primary autoimmune hemolytic anemia (warm antibody)]
1Tokyo Medical College, Hachioji Medical Center.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 1, 1996
Summary
Autoimmune hemolytic anemia is a condition where the body attacks its own red blood cells. Treatment involves corticosteroids, with options like immunosuppression or splenectomy for severe cases.
Area of Science:
- Hematology
- Immunology
- Internal Medicine
Context:
- Primary autoimmune hemolytic anemia (AIHA) affects all ages and sexes.
- Onset can be sudden or gradual, with potential for severe anemia.
- Cardio-respiratory compromise necessitates immediate intervention like blood transfusion.
Purpose:
- To outline the clinical presentation and management strategies for warm-reacting autoimmune hemolytic anemia.
- To detail treatment protocols including corticosteroids, alternative therapies, and supportive care.
Summary:
- Corticosteroids (1-2 mg/kg/day) are the primary treatment for AIHA.
- Treatment involves gradual steroid reduction upon achieving normal hemoglobin levels.
- Refractory cases or those with side effects may require methylprednisolone pulse therapy, immunosuppression, or splenectomy.
- Plasmapheresis can be a temporary measure to rapidly reduce antibody titers.
Impact:
- Provides a concise overview of AIHA diagnosis and management.
- Highlights critical interventions for severe anemia and cardio-respiratory distress.
- Informs clinical decision-making for treatment-resistant AIHA cases.